About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

Regeneron (NASDAQ: REGN) is testing its drug, trevogrumab, along with Wegovy and another treatment, garetosmab, in a ...

Doctors say drugs that improve muscle mass could benefit older or infirm people at greater risk of falls and fractures ...

MIAMI, FL, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ ... reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) -- -- Patients on Enobosarm on average lost 71% ...

In trials of Wegovy, up to 40% of weight loss was from a decrease in lean or fat-free mass, rather than excess fat. These experimental medicines are still a few years from possible approval. Veru ...

Wegovy and Zepbound target the GLP-1 protein to help control appetite. Veru was first with results in January from a 168-person trial, showing its enobosarm helped older patients lose 71% less ...

Veru's enobosarm is designed to be used in combination with GLP-1 agonist-based obesity drugs – such as Novo Nordisk's blockbuster Wegovy (semaglutide) – to reduce the loss of lean muscle mass ...